Mateon Therapeutics   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: South San Francisco CA United States (1988)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2005
NCT00113438
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Mateon Therapeutics | OXiGENE

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Choroidal Neovascularization (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Neoplasms (Phase 1)

Lung Neoplasms (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myopia (Phase 2)

Myopia, Degenerative (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neovascularization, Pathologic (Phase 2)

Neuroendocrine Tumors (Phase 2)

Ovarian Neoplasms (Phase 3)

Thyroid Carcinoma, Anaplastic (Phase 3)

Thyroid Diseases (Phase 3)

Thyroid Neoplasms (Phase 3)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 11